Next Phase Newsletter

A venture capital firm headquartered in the U.S. invests in pre-seed, seed, and opportunistic Series A tech-bio startups across the country. With access to a strong healthcare and life sciences network, the firm connects portfolio companies with strategic partners and resources to accelerate growth. Initial checks typically range from $300K to $1M, often through syndication or co-investment. 

The firm focuses on technology-driven biotechnology companies, particularly those leveraging AI, computational biology, and machine learning to achieve breakthroughs in drug development, diagnostics, precision medicine, and other healthcare innovations. It is indication-agnostic and prioritizes startups where technology forms the core of the value proposition and enables scalable impact. 

The firm does not enforce rigid requirements on company structure or team experience, instead seeking strong technical foundations, visionary leadership, and a clear path to commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm invests in transformative mental health deep tech, including psychedelics and neurotechnology. The firm invests in Pre-Seed, Seed, and Series A companies, aiming to bridge the Series A funding gap and democratize access to frontier modalities at scale. Typical initial investments range from $250,000 to $2 million, with the possibility of follow-on funding. The firm is open to both leading and co-investing in deals, and may take board seats or observer roles on a case-by-case basis. It maintains a global investment scope and is not limited to opportunities within the U.S. 

The firm focuses on transformative technologies that address mental health challenges. Areas of particular interest include psychedelic medicines, especially non-hallucinogenic neuroplastogens (notably NCEs), and short-duration psychedelic compounds aligned with the Spravato medical model. It also invests in digital therapeutics and neurotechnology designed for mental health applications. While the firm is open to early-phase companies, it has a preference for those with strong IP and patent portfolios. It looks for innovations that can make a significant impact on mental health treatments and patient outcomes and places a strong emphasis on ethical conduct. 

The firm does not have strict requirements for founding teams. Its management team, composed of startup founders and operators, provides extensive support to portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm based in North America focuses on making primarily Seed-stage investments but maintains flexibility to invest from Pre-Seed through Series A. It typically writes first checks ranging from USD 100,000 to USD 1 million, with a sweet spot around USD 500,000, and is open to follow-on participation. The firm has a flexible capital structure and can invest via equity, SAFEs, convertible notes, or other early-stage instruments. It is comfortable acting as lead, co-lead, or syndicate participant, and generally makes 6-10 new investments per year. While its geographic focus is North America, the firm is open to global opportunities where companies are looking to expand into the U.S. market. 

The firm invests primarily in digital health companies and selectively in diagnostics and medical devices, particularly those with significant data value or differentiated data-driven technologies. Within digital health, the firm looks broadly at software and AI-enabled solutions. It is also interested in biotech platform technologies, particularly those enabling delivery or translational efficiency, but tends to avoid single-asset drug candidates. In medtech, the firm is open to all device classifications but shows stronger interest in technologies with clear regulatory or technical differentiation, rather than lightly regulated tools. 

A key focus for the firm is the founding team. Team quality is one of the most important decision-making factors, and the firm evaluates teams holistically, including personality, market fit, experience, and leadership traits. The firm prefers to back experienced and well-rounded teams with a clear execution edge. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A pharmaceutical company known as a global leader in consumer healthcare operates a significant prescription pharmaceutical business. Its consumer healthcare portfolio includes over 250 products and generates approximately USD 2.4 billion in sales annually. In recent years, the firm launched an internal innovation unit that was established with the mission of developing new businesses through open innovation or by acquiring new technologies. The firm focuses on early-stage innovation, particularly seed and Series A companies, and explores opportunities via direct investment as well as collaborative research and product licensing. 

The firm targets transformative concepts in healthcare, such as preventative technologies, non-invasive treatments, and early diagnostic tools. The firm typically invests between USD 300,000 and USD 5 million, though the firm does not lead investment rounds. The firm prefers to invest alongside a lead VC or within a syndicate of investors. The firm’s geographic focus lies predominantly in North America and Europe. 

The firm has outlined three priority areas of interest: (1) technologies “beyond the pill,” which includes digital therapeutics, software-based interventions, and medical devices, with a strong emphasis on neurotechnology such as neuromodulation, neurofeedback, and biofeedback; (2) advanced therapies, encompassing novel modalities and emerging therapeutic approaches; and (3) sensing and monitoring technologies, including wearables and vital sign sensing. While the firm does not require board representation, it may seek observer rights when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm backed by a major global financial services group actively invests across multiple sectors, including life sciences. The firm typically invests USD 1–2 million per round, though it is capable of larger allocations depending on the opportunity. While globally active, the firm focuses on opportunities with strong relevance to specific market needs in Asia. 

In the life sciences space, the firm is currently targeting therapeutic and medtech products that address major unmet medical needs in its home market. It favors companies with a clear strategy to collaborate with regional pharmaceutical partners, whether through licensing, co-development, or strategic equity participation. The firm considers a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated drugs. It primarily seeks products in Phase I clinical trials but may also invest in assets within one year of entering the clinic. Indications of strong interest include oncology and orphan diseases. 

The firm only co-invests in opportunities outside of its home country and strongly prefers that a reputable institutional lead or established syndicate be in place before participating. As such, it tends to evaluate international deals with a co-investment mindset alongside other institutional investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This venture capital firm headquartered in Northern Europe, is currently deploying capital from a life science focused fund. The firm primarily invests in biotech and digital health companies based in the Nordic and Baltic regions. The firm participates from Pre-Seed through Series A rounds, typically writing initial checks ranging from €250,000 to €3 million. The firm is open to both leading and co-investing in financing rounds. 

While the firm’s primary focus lies in biotech and digital health, the firm is also open to investing in medical devices and diagnostics. Within biotech, the firm supports companies from the preclinical stage through to Phase I, with Phase II generally considered the latest point of entry. The firm maintains a disease-agnostic approach and is more focused on platform potential and scientific merit than on specific indications. 

In most investments, the firm will seek a board seat, or at minimum, observer rights, reflecting its active involvement and strategic engagement with portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A Europe-based venture capital firm manages a dedicated fund focused on diabetes and related conditions. Its investment sweet spot ranges from Seed to Series A, with typical check sizes between $1–3 million. The firm invests globally and is open to both leading and co-investing. Its team brings strong scientific and industry expertise in the diabetes space and actively supports portfolio companies, including through board and observer roles. 

The firm focuses on diabetes and related indications such as comorbidities or conditions where diabetes is a key driver (e.g., kidney disease, wound care, and vision loss). It primarily invests in medical devices and digital health solutions, avoiding traditional biotech therapeutics. For hardware, the firm seeks technologies beyond the prototype stage with early data (lab, clinical, or first-in-human). For software, it prioritizes products showing commercial traction or scalable business models. For B2B products, validation through partnerships with medtech firms or healthcare systems is a strong advantage. 

There are no specific requirements regarding a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology